For research use only. Not for therapeutic Use.
<p style=/line-height:25px/>Biperiden(KL 373) is an antiparkinsonian agent, which is the selective central M1 cholinoreceptors blocker.<br>Target: M1 receptors<br>Biperiden is an antiparkinsonian agent of the anticholinergic type. It is used for the adjunctive treatment of all forms of Parkinson/’s disease (postencephalitic, idiopathic, and arteriosclerotic)[1]. Biperiden has an atropine-like blocking effect on all peripheral structures which are parasympathetic-innervate. It also has a prominent central blocking effect on M1 receptors [2].<br>Biperiden (0.11 mg/kg), benactyzine (0.3 mg/kg),caramiphen (10 mg/kg), procyclidine (3 mg/kg), and trihexyphenidyl (0.12 mg/kg) separately and each in combination with physostigmine (0.1 mg/kg) is to make a comparative assessment of potential cognitive effects. The results showed that benactyzine, caramiphen, and trihexyphenidyl reduced rats/’ innate preference for novelty, whereas biperiden and procyclidine did not [3].<br>Clinical indications: parkinsonism<br>FDA Approved Date:<br>Toxicity: Drowsiness; vertigo; headache; dizziness<br></p>
| Catalog Number | I003854 |
| CAS Number | 514-65-8 |
| Synonyms | 1-(5-bicyclo[2.2.1]hept-2-enyl)-1-phenyl-3-piperidin-1-ylpropan-1-ol |
| Molecular Formula | C21H29NO |
| Purity | ≥95% |
| Target | AChR |
| Solubility | 10 mM in DMSO |
| Storage | Store at -20C |
| Reference | <p style=/line-height:25px/> |
